A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2018
Price : $35 *
At a glance
- Drugs NSI 566 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; First in man
- Sponsors Neuralstem
- 04 Jun 2018 Results presented in a Neuralstem media release.
- 04 Jun 2018 According to a Neuralstem media release, the company has initiate the second cohort of the study.
- 04 Jun 2018 According to a Neuralstem media release, results from this study are published in the journal Cell Stem Cell.